Equities

SCYNEXIS Inc

SCYNEXIS Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.63
  • Today's Change0.06 / 3.82%
  • Shares traded145.85k
  • 1 Year change-51.92%
  • Beta1.4886
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year SCYNEXIS Inc grew revenues 2,652.72% from 5.09m to 140.14m while net income improved from a loss of 62.81m to a gain of 67.04m.
Gross margin-55.82%
Net profit margin-366.09%
Operating margin-536.96%
Return on assets-26.95%
Return on equity-46.12%
Return on investment-31.99%
More ▼

Cash flow in USDView more

In 2023, cash reserves at SCYNEXIS Inc fell by 11.44m. However, the company earned 60.16m from its operations for a Cash Flow Margin of 42.93%. In addition the company used 34.88m on investing activities and also paid 36.72m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share1.60
Tangible book value per share1.60
More ▼

Balance sheet in USDView more

SCYNEXIS Inc has a Debt to Total Capital ratio of 17.47%, a higher figure than the previous year's 12.49%.
Current ratio3.75
Quick ratio--
Total debt/total equity0.2116
Total debt/total capital0.1747
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.